Abstract:Hepatocellular carcinoma(HCC) has high morbidity and mortality. Arsenic trioxide(ATO), an established therapy for acute promyelocytic leukemia, demonstrates efficacy against HCC. Nano-drug delivery technology is an emerging drug delivery system that can overcome the shortcomings of free ATO usage, such as rapid drug clearance rate, poor tissue distribution specificity, and significant adverse reactions. It has great application potential.This review summarizes ATO's anti-HCC mechanisms, recent advances in ATO-loaded nanocarriers, and their therapeutic potential, while addressing future challenges.
Key words:Hepatocellular carcinoma ; Arsenic trioxide ; Nano-drug delivery ; Mechanism
Funding: Shanghai"Science and Technology Innovation Action Plan"Medical Innovation Project(22Y11921200)
Author:Zhai Xiaofeng, E-mail: zhaixfch@163.com;